Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome–based tumor-informed ctDNA assays in clear cell renal cell carcinoma.

ASCO 2024 methods abstract (Seo first, Tang last): in 5 oligometastatic ccRCC patients, baseline MRD calls from Myriad High-Definition MRD sub-panels designed from primary-tumor vs metastatic subsites were fully concordant in 3 of 5 patients, at tumor fractions from 0.0004% to 0.027%.

ASCO Annual Meeting 2024, Abstract 3039 2024